✦ LIBER ✦

Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia

✍ Scribed by MichaelW.N. Deininger

Publisher: Springer-Verlag
Year: 2004
Tongue: English
Weight: 543 KB
Volume: 130
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-003-0502-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Current status of molecularly targeted t

Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science

✍ Shinji Tanaka; Shigeki Arii 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 420 KB

STI571, a tyrosine kinase inhibitor for

STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy

✍ Michael J. Mauro; Michael E. O'Dwyer; Brian J. Druker 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 66 KB

O37 BCR-ABL kinase domain mutations and

O37 BCR-ABL kinase domain mutations and clonal evolution as major causes of resistance to targeted therapy in chronic myelogenous leukemia

✍ H. Andrikovics; N. Meggyesi; S. Lueff; A. Batai; E. Adam; A. Kozma; G. Halm; S. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Hb-Hana family is the first described example, where partial glutathione reductase deficiency represents a modifying factor of clinical manifestation of unstable hemoglobinopathy. Grant support: MSM 6198959205 and MSM 6198959216. O35 A prognostic impact of transfusion dependency on survival of pati